All In Biotech

Investigational drug · Phase 2

LM101

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Tumors.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "LM101"

First trial start

2023

Jan 11, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LM101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Malignant Tumors

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "LM101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Malignant Tumors

  • LBL-007AlcestobartPhase 38 trials

    BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

  • MK-2010LM-299Phase 24 trials

    Merck & Co. · Advanced Solid Tumors, Malignant Neoplasm, Malignant Tumors

  • LM-364Phase 22 trials

    LaNova Medicines Limited · Advanced Solid Tumor Cancer, Malignant Tumors

  • LM-350Phase 21 trial

    LaNova Medicines Limited · Malignant Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.